CN107582637A - One kind two is to lipid-lowering capsule - Google Patents
One kind two is to lipid-lowering capsule Download PDFInfo
- Publication number
- CN107582637A CN107582637A CN201710897886.8A CN201710897886A CN107582637A CN 107582637 A CN107582637 A CN 107582637A CN 201710897886 A CN201710897886 A CN 201710897886A CN 107582637 A CN107582637 A CN 107582637A
- Authority
- CN
- China
- Prior art keywords
- capsule
- lipid
- eclipta
- lowering
- glossy privet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of Chinese medicinal capsule of reducing blood lipid, is more particularly to one kind two to lipid-lowering capsule.Provided by the invention two include the active component of following parts by weight to lipid-lowering capsule：Glossy privet fruit total triterpenic acid 20 40, eclipta total saposins 50 70, eclipta general flavone 10 20；The capsule also includes pharmaceutically acceptable auxiliary material.Provided by the invention two, to lipid-lowering capsule, are made up, chemical constituent is clear and definite, stable and controllable for quality, and lipid-lowering effect is good of the fruit of glossy privet and Yeradetajo extract that are obtained using modern Hydrolysis kinetics technology.
Description
Technical field
The present invention relates to a kind of Chinese medicinal capsule of reducing blood lipid, is more particularly to one kind two to lipid-lowering capsule.
Background technology
Erzhi pills original name " glossy privet is red ", is made up of the fruit of glossy privet, the taste medicine of eclipta 2.The fruit of glossy privet winter solstice adopts, the eclipta Summer Solstice
Day adopts, therefore named to say erzhi pills, is the classics recipe of tcm clinical practice prolonged application.Its flavour of a drug defective ejaculation and mild in medicine property and, mend without stagnant,
Grow and it is oiliness, be the prescription of enriching yin and nourishing kidney, have liver and kidney benefiting, tonifying yin blood, strengthen the bone, black beard and hair the effect of.
The ability of Deity three《Doctor is just》(into book in 1569, publishing in 1587) is recorded：" erzhi pills, clear upper benefit lower first
Side, inexpensive and work(is very big, informal dress has special effect repeatly, and the winter solstice takes purpleflower holly fruit (i.e. the fruit of glossy privet) to be regardless of how many, dries in the shade, and is mixed with mulse
Thoroughly, box diel, sack wipe skin, dry, and for end, new watt of bottle is harvested and stored.Treat that the summer solstice takes the tens of jin of Eclipta prostrata, smash nature juice
Cream is endured, and prodrug end is ball, as Phoenix Tree Seed is big, often take hundred balls, wine is sent down when facing sleeping.Its work(is very big, just clothes just can make the old without
It is tired from night, not the ten days double muscle power, and can bleaches beard and hair to be black, manages waist and knee, strengthens the bone, strong asthenic yin, wine and women-sensual pursuits convulsive seizure due to phlegm-fire it
People takes, especially more special effect.”
2010 editions《Chinese Pharmacopoeia》Record erzhi pills, now there are some researches show, erzhi pills mainly have immune enhancing, reducing blood lipid,
Antithrombotic, anti-oxidant and protect liver etc. act on.And the early-stage Study of present inventor shows：Erzhi pills has very well to hyperlipidemia
Therapeutic action, serum triglyceride (TG) and LDL-C (LDL-C) can be significantly reduced, hence it is evident that rise it is highly dense
Lipoprotein cholesterol (HDL-C) is spent, is better than Effects of Xuezhikang on antiatherosclerosis index, additionally there is regulation lipid metaboli to close
Key enzyme, improve the multiple actions such as hemorheology, and without obvious toxic-side effects.
Angiocardiopathy is the disease of current threat human health most serious, and it is near that China dies from angiocardiopathy person every year
3000000 people.Hyperlipidemia is to induce the Major Risk Factors of angiocardiopathy, has report to show, I is grown up dyslipidemia at present
Illness rate 18.6%, part developed regions illness rate are more up to more than 30%.Hyperlipidemia is prevented and treated for preventing coronary disease
The angiocardiopathies such as disease, headstroke are significant.At present, the medicine for treating hyperlipidemia mainly has chemical drugs and Chinese medicine,
Because Western medicine product has curative effect fast, mechanism of action is clear, is widely applied clinically, particularly Statins, fibrates
Chemical drugs, brand effectiveness is high, and intervention market is early, and more than 60% is reached in market sales volume.But Western medicine action target spot and drug effect phase
To single, there is many toxic side effects, it is unfavorable for long-term use.Chinese medicine because its Mutiple Targets work and it is safe, increasingly by
To favor, but at present also there is the problems such as chemical composition is complicated, action target spot is unclear, quality is unstable, curative effect is also not as changing
It is notable to learn medicine.Therefore exploitation drug effect is notable, active ingredient clearly, action target spot understand, modern Chinese herbal medicine stable and controllable for quality
As development trend.
Present inventor uses the theory and pattern of component compatibility, and " erzhi pills " is furtherd investigate, utilizes the modern times
Hydrolysis kinetics technology obtains the fruit of glossy privet and each active ingredient of eclipta, completes the fruit of glossy privet and eclipta reducing blood lipid active princlple group
Determination, and utilize inside and outside screening model, it is determined that the optimization blends and preparation process of active princlple group, succeeded in developing more
Target spot action, drug effect is obvious, chemical composition is clearer and more definite, stable and controllable for quality two to lipid-lowering capsule.
The content of the invention
It is an object of the invention to provide a kind of chemical composition is clear and definite, lipid-lowering effect is good, stable and controllable for quality two to
Lipid-lowering capsule.
The invention provides one kind two to lipid-lowering capsule, the capsule to include the active component of following weight parts：
Glossy privet fruit total triterpenic acid 20-40, eclipta total saposins 50-70, eclipta general flavone 10-20；
Described glossy privet fruit total triterpenic acid extracts from the fruit of glossy privet；
Described eclipta total saposins extract from eclipta；
Described eclipta general flavone extracts from eclipta.
Preferably, the capsule includes the active component of following weight parts：
Glossy privet fruit total triterpenic acid 25-35, eclipta total saposins 55-65, eclipta general flavone 12-18；
It is highly preferred that the capsule includes the active component of following weight parts：
Glossy privet fruit total triterpenic acid 30, eclipta total saposins 60, eclipta general flavone 15.
Further, of the present invention two also include pharmaceutically acceptable auxiliary material to lipid-lowering capsule；
Preferably, described auxiliary material is selected from sucrose, dextrin, starch, talcum powder, microcrystalline cellulose, hydroxypropyl cellulose, shell
One or more in glycan, polyvidone；
Preferably, the combination of one or both of the described auxiliary material in microcrystalline cellulose and sodium carboxymethyl starch；
It is highly preferred that described auxiliary material is the microcrystalline cellulose and sodium carboxymethyl starch that weight ratio is 1: 1.
Further, of the present invention two into lipid-lowering capsule, described glossy privet fruit total triterpenic acid, the total soap of eclipta
The weight ratio of glycosides, the total amount of eclipta general flavone and auxiliary material is 0.5-3；
Preferably, the weight of described glossy privet fruit total triterpenic acid, eclipta total saposins, the total amount of eclipta general flavone and auxiliary material
Amount is than being 2.
Of the present invention two can be prepared by the step of following orders to lipid-lowering capsule：
After glossy privet fruit total triterpenic acid, eclipta total saposins, eclipta general flavone are mixed by formula dosage, add formula and use
The auxiliary material of amount, mix, fill capsule.
The fruit of glossy privet：The dry mature fruit of oleaceae plant glossy privet.
Eclipta：The dry aerial parts of feverfew Eclipta prostrata.
The beneficial effects of the present invention are：Provided by the invention two to lipid-lowering capsule, by utilizing modern Hydrolysis kinetics technology
The fruit of glossy privet of acquisition and the extract of eclipta are made, and chemical constituent is clear and definite, stable and controllable for quality, and lipid-lowering effect is good.
Embodiment
The present invention can be further well understood by the specific embodiment and comparative example of invention now given below.
But they are not limitation of the invention.
The fruit of glossy privet as described below and eclipta medicinal material are purchased from Hangzhou East China prepared slices of Chinese crude drugs Co., Ltd.
The preparation of the glossy privet fruit total triterpenic acid of embodiment 1
Glossy privet fruit total triterpenic acid of the present invention is prepared by following methods：
Fruit of glossy privet powder is taken, 70% ethanol of 15 times of amounts will be added in fruit of glossy privet powder, circumfluence distillation 2 times, carried every time
Take 2h；
Extract solution is concentrated into 0.2g crude drugs/mL, regulation pH is 8.0, is adsorbed onto on AB-8 macroreticular resins, loading flow velocity is
4 column volume/h, 5 column volumes are washed, 90% column volume of ethanol elution 4, the eluent of 90% ethanol elution is collected, depressurizes
It is concentrated to give glossy privet fruit extract；
After testing, triterpenic acid containing glossy privet fruit total 50% in the glossy privet fruit extract.
The preparation of the eclipta total saposins of embodiment 2
Eclipta powder is taken, eclipta powder is soaked into 0.5h with 70% ethanol, then with the 70% ethanol heat of 20 times of amounts
Refluxing extraction 1h, then extract 0.5h with 70% alcohol heat reflux of 16 times of amounts；
Extract solution is concentrated into 0.25g crude drugs/mL, is adsorbed onto on AB-8 macroreticular resins, loading flow velocity be 3 column volumes/
H, 4 column volumes are washed, 70% column volume of ethanol elution 4, collect the eluent of 70% ethanol elution, be concentrated under reduced pressure to obtain black drought
Lotus extract 1；
After testing, total saposins containing eclipta 55% in the Yeradetajo extract 1.
The preparation of the eclipta general flavone of embodiment 3
Eclipta powder is taken, eclipta powder is soaked into 0.5h with 70% ethanol, then with the 70% ethanol heat of 20 times of amounts
Refluxing extraction 1h, then extract 0.5h with 70% alcohol heat reflux of 16 times of amounts；
Extract solution is concentrated into 0.25g crude drugs/mL, is adsorbed onto on AB-8 macroreticular resins, loading flow velocity be 3 column volumes/
H, 4 column volumes are washed, 40% column volume of ethanol elution 3, collect the eluent of 40% ethanol elution, be concentrated under reduced pressure to obtain black drought
Lotus extract 2；
After testing, general flavone containing eclipta 45% in the Yeradetajo extract 2.
Embodiment 4
One kind two to lipid-lowering capsule, capsule includes following components in parts by weight：
Said components are mixed, fill No. 1 capsule, every capsule weight 0.2g.
Embodiment 5
One kind two to lipid-lowering capsule, capsule includes following components in parts by weight：
Said components are mixed, fill No. 1 capsule, every capsule weight 0.2g.
Embodiment 6
One kind two to lipid-lowering capsule, capsule includes following components in parts by weight：
Said components are mixed, fill No. 1 capsule, every capsule weight 0.2g.
Comparative example 1
One kind two to lipid-lowering capsule, capsule includes following components in parts by weight：
Said components are mixed, fill No. 1 capsule, every capsule weight 0.2g.
Comparative example 2
One kind two to lipid-lowering capsule, capsule includes following components in parts by weight：
Said components are mixed, fill No. 1 capsule, every capsule weight 0.2g.
Comparative example 3
One kind two to lipid-lowering capsule, capsule includes following components in parts by weight：
Said components are mixed, fill No. 1 capsule, every capsule weight 0.2g.
Comparative example 4
Prepare traditional erzhi pills：The fruit of glossy privet, eclipta (each 500g) crush, finely ground, cross 20 mesh sieves, add water to cook 3 times, the
1 time plus 10 times amount water, the 2nd time plus 8 times amount water, the 3rd time plus 8 times amount water, each 2h merge decoction liquor, filtering, and filtrate is concentrated into
The thick paste that relative density is 1.30 produces.
The blood fat reducing function of experimental example 1 compares
Establish olive Antihyperlipidemia capsule：
High lipid food, ad lib and drinking-water are fed to 200g or so male Wistar rats.Separately set feeding chow diet
Rat make negative control.Posterior orbit takes hematometry lipids contents within two weeks, with judgment models success.
Administration：
Dyslipidemia rat is grouped at random, every group 5, respectively with embodiment 4, embodiment 5, embodiment 6, contrast
The two traditional erzhi pillses (dosage is 150mg/kg) provided to lipid-lowering capsule, comparative example 4 and Effects of Xuezhikang that example 1 provides (are used
Dose 600mg/kg) mouse is fed, once a day, posterior orbit takes blood within 4 weeks；
Full automatic biochemical apparatus determines 4 contents of blood fat：Including cholesterol (TC), triglycerides (TG), low-density lipoprotein
Cholesterol (LDL-C) and HDL-C (HDL-C)；
Reducing blood lipid the results are shown in Table 1 after being administered 4 weeks；
Table 1
The hydroscopicity of experimental example 2 detects
Embodiment 4, embodiment 5, embodiment 6, comparative example 2, the two of the offer of comparative example 3 are mixed respectively to lipid-lowering capsule
Even component takes in right amount, inserts added with P2O5Drier in dry 48h, while bottom is filled to the glass of NaCl supersaturated solutions
Glass drier is put into 24h in 25 DEG C of insulating box, and its internal relative humidity is 75%.Added in the measuring cup for drying constant weight
The component that appropriate each group mixes, it is placed in above-mentioned glass desicator after precise weighing, timing sampling weighs, and counts according to the following equation
Hydroscopicity is calculated, each group different time hydroscopicity measurement result is shown in Table 2：
Hydroscopicity=[constituent mass before (constituent mass before constituent mass-moisture absorption after moisture absorption)/moisture absorption] × 100%
Table 2
| Group | 6h | 12h | 24h | 48h | 60h |
| Embodiment 4 | 2.56 | 4.53 | 6.49 | 8.03 | 9.65 |
| Embodiment 5 | 2.61 | 4.82 | 6.75 | 8.16 | 9.84 |
| Embodiment 6 | 1.65 | 3.17 | 5.23 | 6.07 | 6.82 |
| Comparative example 2 | 2.94 | 5.16 | 7.17 | 8.86 | 10.45 |
| Comparative example 3 | 2.87 | 5.08 | 7.14 | 8.79 | 10.38 |
Claims (9)
1. one kind two to lipid-lowering capsule, capsule includes the active component of following parts by weight：
Glossy privet fruit total triterpenic acid 20-40, eclipta total saposins 50-70, eclipta general flavone 10-20.
2. according to claim 1 two include the active component of following parts by weight to lipid-lowering capsule, the capsule：
Glossy privet fruit total triterpenic acid 25-35, eclipta total saposins 55-65, eclipta general flavone 12-18.
3. according to claim 1 two include the active component of following parts by weight to lipid-lowering capsule, the capsule：
Glossy privet fruit total triterpenic acid 30, eclipta total saposins 60, eclipta general flavone 15.
4. according to claim any one of 1-3 two to lipid-lowering capsule, wherein, the capsule also includes pharmaceutically acceptable
Auxiliary material.
5. according to claim 4 two to lipid-lowering capsule, wherein, described auxiliary material is selected from sucrose, dextrin, starch, talcum
One or more in powder, microcrystalline cellulose, hydroxypropyl cellulose, chitosan, polyvidone.
6. according to claim 5 two to lipid-lowering capsule, wherein, described auxiliary material is selected from microcrystalline cellulose and carboxymethyl forms sediment
The combination of one or both in powder sodium.
7. according to claim 6 two to lipid-lowering capsule, wherein, described auxiliary material is the microcrystalline cellulose that weight ratio is 1: 1
Element and sodium carboxymethyl starch.
8. according to claim any one of 5-7 two to lipid-lowering capsule, wherein, described glossy privet fruit total triterpenic acid, ink drought
The weight ratio of lotus total saposins, the total amount of eclipta general flavone and auxiliary material is 0.5-3.
9. according to claim 8 two to lipid-lowering capsule, wherein, described glossy privet fruit total triterpenic acid, eclipta total saposins,
The total amount of eclipta general flavone and the weight ratio of auxiliary material are 2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710897886.8A CN107582637B (en) | 2017-09-28 | 2017-09-28 | One kind two is to lipid-lowering capsule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710897886.8A CN107582637B (en) | 2017-09-28 | 2017-09-28 | One kind two is to lipid-lowering capsule |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107582637A true CN107582637A (en) | 2018-01-16 |
| CN107582637B CN107582637B (en) | 2019-02-26 |
Family
ID=61047275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710897886.8A Active CN107582637B (en) | 2017-09-28 | 2017-09-28 | One kind two is to lipid-lowering capsule |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107582637B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102247420A (en) * | 2011-07-04 | 2011-11-23 | 浙江大学 | Preparation method and application of eclipta extract |
-
2017
- 2017-09-28 CN CN201710897886.8A patent/CN107582637B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102247420A (en) * | 2011-07-04 | 2011-11-23 | 浙江大学 | Preparation method and application of eclipta extract |
Non-Patent Citations (3)
| Title |
|---|
| 刘春美等: "加味二至胶囊对大鼠复合型脂肪肝的调脂保肝作用", 《药学与临床研究》 * |
| 姚干等: "正交设计法配合多药效指标综合评价筛选二至丸有效部位群组方的最", 《中成药》 * |
| 李瑞明等: "丹墨胶囊的薄层色谱鉴别", 《中国医药导报》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107582637B (en) | 2019-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101797346B (en) | Qiqing traditional Chinese medicine tea for lowering blood pressure, lowering blood lipid and lowering blood sugar level and preparation method thereof | |
| CN102727680B (en) | Traditional Chinese medicine for reducing blood fat, and preparation method thereof | |
| CN104083727A (en) | Traditional Chinese medicine composition for nourishing and protecting liver | |
| CN107853517B (en) | Traditional Chinese medicine beverage capable of refreshing and resisting fatigue and preparation method thereof | |
| CN108057039A (en) | A kind of Dendrobium officinale polysaccharide and Siberian solomonseal rhizome polysaccharide composition and preparation method and application | |
| CN108404062A (en) | Treat the Chinese medicine composition and its preparation method and application of hyperlipidemia | |
| CN104138526B (en) | A kind of root of three-nerved spicebush iron sheet ginseng granules agent | |
| CN103585245B (en) | Preparation method, extract and its application of common pratia herb extract | |
| CN103749818A (en) | Rhizoma polygonati healthcare tea with hypoglycemic and hypolipidemic effects and preparation method thereof | |
| CN109247560A (en) | A kind of fermented type seasoning rose cooking wine and preparation method thereof | |
| CN102068521A (en) | Traditional Chinese medicine composition for treating hyperlipidemia and preparation method and application thereof | |
| CN102846879A (en) | Composition for depressing blood fat | |
| CN107582637B (en) | One kind two is to lipid-lowering capsule | |
| CN106535912A (en) | Pharmaceutical composition for controlling blood lipids and body weight, and use thereof | |
| CN109303800A (en) | A kind of lowering fat and protecting liver composition and its preparation method and application | |
| CN101181318A (en) | Shanlu Tea extract for dropping blood pressure and blood fat as well as preparation method thereof | |
| CN101020016A (en) | Medicine for treating fracture and injured tendon and its prepn | |
| CN100393334C (en) | A method for preparing fat-reducing medicine | |
| CN109316565B (en) | Blood fat reducing composition and preparation method and application thereof | |
| CN105477213A (en) | Traditional Chinese medicine composition for reducing blood fat and preparing method thereof | |
| CN1115159C (en) | Red sage containing medicine composition and its preparation and use | |
| CN111870626B (en) | Pharmaceutical composition with blood fat reducing effect and preparation method and application thereof | |
| CN106860656A (en) | It is a kind of to treat Chinese medicine composition of osteoporosis and its preparation method and application | |
| CN101375978A (en) | Medicinal composition for lowering blood fat | |
| CN103877513A (en) | Chinese herbal compound composition with blood fat reduction effect, and applications thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |